Page 110 - NobleCon20-Book-Project

Health Care
Date November 19, 2024 Health Care
52wk High $3.83
52wk Low $2.05 Lisata Therapeutics, Inc. LSTA $2.79
110 Allen Road
Basking Ridge, NJ 07920

(USD - in millions) www.lisata.com
Market Cap 23.7
Enterprise (12.4)
Basic Shares Out. 8.32 COMPANY OVERVIEW
Float 6.96
Institutional Holdings 9.21% Detailed Analysis:Channelchek.com
Short Interest 0.02 Lisata Therapeutics is a clinical-stage pharmaceutical company
Avg. 90-Day Volume 0.01 dedicated to the discovery, development and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s internalizing RGD, or
Arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate,
EPS Data certepetide, is an investigational drug designed to activate a novel
uptake pathway that allows co-administered or tethered anti-cancer
2022 2023 2024 drugs to selectively target and penetrate solid tumors more effectively.
CQ1 (1.05) (0.77) (0.65) The Company expects to announce numerous milestones over the next
CQ2 (1.65) (0.50) (0.61) 1.5 years and believes that its projected capital will fund operations into
early 2026, encompassing anticipated data milestones from its ongoing
CQ3 (1.47) (0.65) (0.59) and planned clinical trials.
CQ4 (0.76) (0.66) (0.73)
CY (4.60) (2.58) (2.68) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 4.05
ROE (ttm) -48.15
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
110 Allen Roa Basking RidgeNJ 07920

Key Executives
CEO: Mazzo, David
CFO: Nisco, James
COO: Imam, Tariq
IR: Menditto, John
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures